Symbol | Exchange | Currency |
|---|
Evgen Pharma PLC (LONEVG) has announced progress for its lead asset on two fronts in the field of cancer. In the US, it has applied to the Food & Drug Administration for orphan...
Evgen Pharma PLC (LONEVG) has announced progress for its lead asset on two fronts in the field of cancer. In the US, it has applied to the Food & Drug Administration for orphan...
Open Orphan PLC (LON:ORPH) said its hVIVO subsidiary has won a deal to test an antiviral in human challenge studies using both the common cold and flu virus. It will be working...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Sell |
| Technical Indicators | Sell | Sell | Buy | Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Neutral | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 269.50 | 275.80 | 268.50 | -10.50 | -3.75% | 7.87M | London | |||
| 305.40 | 315.00 | 303.20 | -17.80 | -5.51% | 1.13M | London | |||
| 349.60 | 373.20 | 345.40 | -15.40 | -4.22% | 503.97K | London | |||
| 52.93 | 53.04 | 50.10 | +1.84 | +3.60% | 7.53M | London | |||
| 240.70 | 245.05 | 237.10 | +0.70 | +0.29% | 30.40K | London | |||
| 221.50 | 225.45 | 218.50 | -6.00 | -2.64% | 50.84K | London | |||
| 113.44 | 114.32 | 112.82 | -0.88 | -0.77% | 17.22M | London | |||
| 300.90 | 303.25 | 299.70 | -3.75 | -1.23% | 22.22M | London | |||
| 288.54 | 291.30 | 280.00 | +6.20 | +2.19% | 3.48M | London | |||
| 152.42 | 154.88 | 149.06 | +2.92 | +1.95% | 19.85M | London | |||
| 178.15 | 180.55 | 177.65 | -4.25 | -2.33% | 2.33M | London | |||
| 514.84 | 530.00 | 524.00 | +4.00 | +0.77% | 9.98K | London | |||
| 220.00 | 246.00 | 219.00 | -20.60 | -8.56% | 1.62M | London | |||
| 4,586.50 | 4,710.00 | 4,546.00 | -243.0 | -5.03% | 2.24M | London | |||
| 1,348.00 | 1,402.00 | 1,348.00 | -64.00 | -4.53% | 9.43K | London |
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.